Abstract:
Pyrazoline is a secondary metabolic compound containing five circular heterocyclic
structures, comprising three carbon atoms and two nitrogen atoms positioned closely to
each other. Due to its high toxicity, Pyrazoline exhibits diverse bioactivities, including
antitumor and anticancer properties. Pyrazoline (2-(5-3-bromophenyl)-1-phenyl-4,5-
dihydro-1H-pyrazole-3-yl)naphtalene-1-ol) has been successfully synthesized through
several phases of reaction. The first phase involves the formation of chalcone 3-(3-
bromophenyl)-1-(1-hydroxynaphthalene-2-yl)-2-propen-1-one by reacting the
compound 1-hydroxy-2-acetylnaphthalene with 3-bromobenzaldehyde using the
microwave irradiation method. Chalcone was synthesized using Claisen-Schmidt
condensation reactions, resulting in a yield of 85.86%. In the subsequent step, chalcone
was reacted with phenylhydrazine, leading to the desired compound in the presence of a
sodium hydroxide catalyst. The synthesis of the target compound employed stirring and
heating with seal tube, yielding 40.18%. The purification of the Pyrazoline compound
was achieved through recrystallization. Its purity was assessed using TLC test, melting
point determination, and HPLC analysis. Furthermore, the confirmation of its structure
was based on spectroscopic data from UV, FTIR and LCMS. The molecular docking of
PF-NH1-3Br against Estrogen α receptors revealed a free bond energy (ΔGbind) of -9,5
kcal/mol.
